1. Home
  2. ATNM vs IMRX Comparison

ATNM vs IMRX Comparison

Compare ATNM & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATNM
  • IMRX
  • Stock Information
  • Founded
  • ATNM 2000
  • IMRX 2008
  • Country
  • ATNM United States
  • IMRX United States
  • Employees
  • ATNM N/A
  • IMRX N/A
  • Industry
  • ATNM Biotechnology: Pharmaceutical Preparations
  • IMRX Biotechnology: Pharmaceutical Preparations
  • Sector
  • ATNM Health Care
  • IMRX Health Care
  • Exchange
  • ATNM Nasdaq
  • IMRX Nasdaq
  • Market Cap
  • ATNM 56.5M
  • IMRX 62.7M
  • IPO Year
  • ATNM N/A
  • IMRX 2021
  • Fundamental
  • Price
  • ATNM $1.40
  • IMRX $2.02
  • Analyst Decision
  • ATNM Strong Buy
  • IMRX Buy
  • Analyst Count
  • ATNM 4
  • IMRX 7
  • Target Price
  • ATNM $8.75
  • IMRX $12.80
  • AVG Volume (30 Days)
  • ATNM 342.1K
  • IMRX 4.9M
  • Earning Date
  • ATNM 11-14-2024
  • IMRX 02-28-2025
  • Dividend Yield
  • ATNM N/A
  • IMRX N/A
  • EPS Growth
  • ATNM N/A
  • IMRX N/A
  • EPS
  • ATNM N/A
  • IMRX N/A
  • Revenue
  • ATNM $81,000.00
  • IMRX N/A
  • Revenue This Year
  • ATNM $138.42
  • IMRX N/A
  • Revenue Next Year
  • ATNM $19,479.88
  • IMRX N/A
  • P/E Ratio
  • ATNM N/A
  • IMRX N/A
  • Revenue Growth
  • ATNM N/A
  • IMRX N/A
  • 52 Week Low
  • ATNM $1.10
  • IMRX $1.00
  • 52 Week High
  • ATNM $10.24
  • IMRX $7.68
  • Technical
  • Relative Strength Index (RSI)
  • ATNM 56.03
  • IMRX 47.82
  • Support Level
  • ATNM $1.18
  • IMRX $1.84
  • Resistance Level
  • ATNM $1.48
  • IMRX $3.80
  • Average True Range (ATR)
  • ATNM 0.10
  • IMRX 0.29
  • MACD
  • ATNM 0.01
  • IMRX -0.03
  • Stochastic Oscillator
  • ATNM 75.00
  • IMRX 9.18

About ATNM Actinium Pharmaceuticals Inc. (Delaware)

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

About IMRX Immuneering Corporation

Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.

Share on Social Networks: